Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 5
Submit an article Journal homepage
1,702
Views
20
CrossRef citations to date
0
Altmetric
Original Research

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial

O. AdoteviUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, France;University Hospital of Besançon, Department of Medical Oncology, F-25000Besançon, FranceCorrespondence[email protected]
View further author information
,
Y. GodetUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, FranceView further author information
,
J. GalaineUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, FranceView further author information
,
Z. LakkisUniversity Hospital of Besançon, Department of Gastrointestinal and liver surgery, F-25000Besançon, FranceORCID Iconhttp://orcid.org/0000-0002-2608-5896View further author information
ORCID Icon,
I. IdireneUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, FranceView further author information
,
J. M. CertouxUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, FranceView further author information
,
M. JaryUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, France;University Hospital of Besançon, Department of Medical Oncology, F-25000Besançon, FranceView further author information
,
R. LoyonUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, FranceView further author information
,
C. LaheurteUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, France;Etablissement Français du Sang Bourgogne Franche-Comté, plateforme de BioMonitoring, F-25000Besançon, France;INSERM CIC-1431, University Hospital of Besançon, Clinical Investigation Center in Biotherapy, F-25000, Besançon, FranceView further author information
,
S. KimUniversity Hospital of Besançon, Department of Medical Oncology, F-25000Besançon, FranceView further author information
,
A. DormoyEtablissement Français du Sang Bourgogne Franche-Comté, F-25000Besançon, FranceView further author information
,
F. PouthierEtablissement Français du Sang Bourgogne Franche-Comté, F-25000Besançon, FranceView further author information
,
C. BarisienEtablissement Français du Sang Bourgogne Franche-Comté, F-25000Besançon, FranceView further author information
,
F. FeinUniversity Hospital of Besançon, Department of Gastroenterology, F-25000Besançon, FranceView further author information
,
P. TiberghienUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, FranceView further author information
,
X. PivotUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, France;University Hospital of Besançon, Department of Medical Oncology, F-25000Besançon, FranceView further author information
,
S. Valmary-DeganoUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, France;University Hospital of Besançon, Department of Pathology, F-25000Besançon, FranceView further author information
,
C. FerrandUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, FranceView further author information
,
P. MorelEtablissement Français du Sang Bourgogne Franche-Comté, F-25000Besançon, FranceView further author information
,
E. DelabrousseUniversity Hospital of Besançon, Department of Radiology, F-25000, Besançon, FranceView further author information
&
C. BorgUniversity Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000Besançon, France;University Hospital of Besançon, Department of Medical Oncology, F-25000Besançon, FranceCorrespondence[email protected]
View further author information
 show all
Article: e1424673 | Received 29 Sep 2017, Accepted 03 Jan 2018, Published online: 19 Mar 2018

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (20)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.